New validated HPLC methodology for the determination of (−)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase

A new chromatographic method for the enantioseparation and the determination of (−)-trans-paroxetine and (+)-trans-paroxetine has been developed with the aid of amylose ovomucoid-based chiral stationary phase. The method is faster and five times more sensitive than procedures recommended previously:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisowska-Kuźmicz, Małgorzata, Kantor-Boruta, Małgorzata, Jończyk, Anna, Jarończyk, Małgorzata, Ocios-Bębenek, Agnieszka, Mazurek, Aleksander P., Chilmonczyk, Zdzisław, Jarosz, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026622/
https://www.ncbi.nlm.nih.gov/pubmed/24408298
http://dx.doi.org/10.1007/s00216-013-7565-y
Descripción
Sumario:A new chromatographic method for the enantioseparation and the determination of (−)-trans-paroxetine and (+)-trans-paroxetine has been developed with the aid of amylose ovomucoid-based chiral stationary phase. The method is faster and five times more sensitive than procedures recommended previously: limit of detection and limit of quantification are 5 and 16 ng/mL, respectively [modified (Ferretti et al. in J Chromatogr B 710:157–164, 1998): 20 and 60 ng/mL]. It was carefully validated and applied for the determination of (−)-trans-paroxetine and (+)-trans-paroxetine in Parogen (Mc Dermott Laboratories Ltd.) and Xetanor (Actavis) coated tablets. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00216-013-7565-y) contains supplementary material, which is available to authorized users.

Ejemplares similares